https://io-therapeutics.com/2013-01-12T00:54:24-08:00https://io-therapeutics.com/about/overview/2024-12-18T14:23:19-08:00https://io-therapeutics.com/about/board-of-directors/2020-06-29T08:35:08-07:00https://io-therapeutics.com/about/advisors/2013-02-06T12:04:49-08:00https://io-therapeutics.com/programs/2025-10-13T16:12:54-07:00https://io-therapeutics.com/programs/5183-2/2023-09-12T14:05:59-07:00https://io-therapeutics.com/news-pess/2025-12-11T16:51:21-08:00https://io-therapeutics.com/programs/discovery/2023-09-12T14:10:30-07:00https://io-therapeutics.com/about/contact/2024-05-13T10:18:45-07:00https://io-therapeutics.com/news-pess/media-releases/2023-09-12T11:12:10-07:00https://io-therapeutics.com/about/2013-01-14T16:19:52-08:00https://io-therapeutics.com/programs/4204-2/2023-09-12T14:10:00-07:00https://io-therapeutics.com/irx4204-as-a-potential-disease-modifying-treatment-for-alzheimers-disease/2020-08-14T13:17:33-07:00https://io-therapeutics.com/io-therapeutics-inc-announces-initiation-of-dosing-in-a-phase-ii-clinical-trial-of-irx4204-in-patients-with-advanced-prostate-cancer/2020-08-14T13:16:33-07:00https://io-therapeutics.com/sample-page/download-document-test/2013-01-15T16:49:17-08:00https://io-therapeutics.com/io-therapeutics-inc-announces-collaboration-with-the-michael-j-fox-foundation-for-parkinsons-research-for-evaluation-of-irx4204-as-a-potential-treatment-for-parkinsons-disease/2020-08-14T13:15:51-07:00https://io-therapeutics.com/news-eventspress-releases/2020-08-14T13:16:47-07:00https://io-therapeutics.com/programs/patents/2024-12-21T17:58:44-08:00https://io-therapeutics.com/publications/2020-11-18T09:02:12-08:00https://io-therapeutics.com/publications/irx4204/2026-03-06T14:20:52-08:00https://io-therapeutics.com/publications/irx5183/2023-09-12T14:25:52-07:00https://io-therapeutics.com/publications/posters/2025-12-11T07:46:17-08:00https://io-therapeutics.com/presentations/2025-12-03T10:51:16-08:00https://io-therapeutics.com/publications/irx4647/2023-09-12T14:31:35-07:00https://io-therapeutics.com/programs/irx4647-2/2024-12-22T16:07:14-08:00